| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity S Spranger, R Bao, TF Gajewski Nature 523 (7559), 231-235, 2015 | 2675 | 2015 |
| Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells S Spranger, RM Spaapen, Y Zha, J Williams, Y Meng, TT Ha, TF Gajewski Science translational medicine 5 (200), 200ra116-200ra116, 2013 | 1868 | 2013 |
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors SR Woo, MB Fuertes, L Corrales, S Spranger, MJ Furdyna, MYK Leung, ... Immunity 41 (5), 830-842, 2014 | 1729 | 2014 |
| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1449 | 2016 |
| Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy S Spranger, D Dai, B Horton, TF Gajewski Cancer cell 31 (5), 711-723. e4, 2017 | 1288 | 2017 |
| Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly … S Spranger, HK Koblish, B Horton, PA Scherle, R Newton, TF Gajewski Journal for immunotherapy of cancer 2, 1-14, 2014 | 635 | 2014 |
| Impact of oncogenic pathways on evasion of antitumour immune responses S Spranger, TF Gajewski Nature Reviews Cancer 18 (3), 139-147, 2018 | 634 | 2018 |
| WNT/β-catenin pathway activation correlates with immune exclusion across human cancers JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski Clinical Cancer Research 25 (10), 3074-3083, 2019 | 572 | 2019 |
| Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment TF Gajewski, SR Woo, Y Zha, R Spaapen, Y Zheng, L Corrales, ... Current opinion in immunology 25 (2), 268-276, 2013 | 472 | 2013 |
| Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma S Spranger, JJ Luke, R Bao, Y Zha, KM Hernandez, Y Li, AP Gajewski, ... Proceedings of the National Academy of Sciences 113 (48), E7759-E7768, 2016 | 394 | 2016 |
| Innate immune signaling and regulation in cancer immunotherapy L Corrales, V Matson, B Flood, S Spranger, TF Gajewski Cell research 27 (1), 96-108, 2017 | 373 | 2017 |
| Increased demand for NAD+ relative to ATP drives aerobic glycolysis A Luengo, Z Li, DY Gui, LB Sullivan, M Zagorulya, BT Do, R Ferreira, ... Molecular cell 81 (4), 691-707. e6, 2021 | 367 | 2021 |
| Molecular drivers of the non–T-cell-inflamed tumor microenvironment in urothelial bladder cancer RF Sweis, S Spranger, R Bao, GP Paner, WM Stadler, G Steinberg, ... Cancer immunology research 4 (7), 563-568, 2016 | 342 | 2016 |
| Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment S Spranger International immunology 28 (8), 383, 2016 | 314 | 2016 |
| Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202–216. doi: 10.1158/2159-8290 W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... CD-15-0283.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 2018 | 309 | 2018 |
| Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy L Zhai, S Spranger, DC Binder, G Gritsina, KL Lauing, FJ Giles, ... Clinical cancer research 21 (24), 5427-5433, 2015 | 303 | 2015 |
| Cancer immunotherapy targets based on understanding the T cell-inflamed versus non-T cell-inflamed tumor microenvironment TF Gajewski, L Corrales, J Williams, B Horton, A Sivan, S Spranger Tumor immune microenvironment in cancer progression and cancer therapy, 19-31, 2017 | 276 | 2017 |
| Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL D Nagel, S Spranger, M Vincendeau, M Grau, S Raffegerst, B Kloo, ... Cancer cell 22 (6), 825-837, 2012 | 266 | 2012 |
| Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity E Duong, TB Fessenden, E Lutz, T Dinter, L Yim, S Blatt, A Bhutkar, ... Immunity 55 (2), 308-323. e9, 2022 | 223 | 2022 |
| WNT signaling in cancer immunosurveillance L Galluzzi, S Spranger, E Fuchs, A López-Soto Trends in cell biology 29 (1), 44-65, 2019 | 214 | 2019 |
Thomas F GajewskiProfessor, University of ChicagoEmail verificata su medicine.bsd.uchicago.edu